Evidence map›Paper›PMID 42004034›Full record

ReviewiScience2026

Current trends, applications, and challenges in three-dimensional bioprinting for cardiovascular disease models and therapies.

Bo Wang, Jing Zhang, Jipin Jiang, Chen Cheng, Yuanyuan Zhao

Abstract readReview
In one paragraph

Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bo WangDepartment of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jing ZhangDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Jipin JiangInstitute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation of Ministry of Education, National Health Commission and Chinese Academy of Medical Sciences, Wuhan, China.
Chen ChengUltrasound Diagnosis Department, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yuanyuan ZhaoInstitute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation of Ministry of Education, National Health Commission and Chinese Academy of Medical Sciences, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of death worldwide. Although conventional treatments such as surgery and transplantation have improved patient survival, they are subject to major limitations. Three-dimensional (3D) bioprinting presents new opportunities for treating CVDs, with the long-term objective of fabricating functional tissues that faithfully replicate native cardiac structure and key physiological functions, including contractile force, electrical conduction, and mechanical integrity. This review outlines the use of 3D bioprinting in modeling principal cardiac disorders, such as arrhythmias, structural heart defects, myocardial infarction, cardiac fibrosis, and heart failure. It further assesses the utility of bioprinting in developing disease models and advancing clinical therapies for these conditions. Finally, we address the ongoing challenges in implementing bioprinting and cardiac tissue engineering for CVDs and suggest possible avenues for improvement. Future studies should prioritize clinical translation and long-term follow-up to evaluate the durability and viability of bioprinted cardiac tissues.

Indexed as

BioengineeringBiomaterialsBiotechnologyCardiovascular medicineTissue engineering

Identifiers

PMID42004034
PMCPMC13091520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.